“We have worked with ARCH Venture Partners since their founding over 30 years ago and are thrilled to be part of this effort. Current events have shown us how important research in the biotech field is and the implications that such funding c...
Below I have added to the previous chart the SPDR® S&P® Biotech ETF (XBI: the black line) which has about 105 holdings, but the positions are equally-weighted which tilts it toward the smaller companies, not just larger companies. As you can see by the black line below, over the...